Arius's Therapeutic Antibody Inhibits Leukemic Cancer Stem Cells
Posted on: Thursday, 14 February 2008, 12:00 CST
Arius Research has said that in preclinical studies the company's anti-CD9 cancer stem cell antibody not only targeted leukemia cancer stem cells, but also led to a dramatic reduction in their capacity to self-renew or give rise to further leukemia.
The company has disclosed the activity of Arius's anti-CD9 antibody, AR40A746.2.3, against acute myeloid leukemia (AML). CD9 appears to be an important driver for leukemia and potentially other cancer stem cells, which often survive treatment, continue to multiply and go on to seed new tumors.
Daniel Pereira, vice president of research at Arius, said: "Our antibody also appears to be a specific cancer stem cell inhibitor, suggesting that it may become an important drug and forge new paths for the treatment of cancer."
Source: Datamonitor
Related Articles
- Scientists Discover Bladder Cancer Stem Cell
- Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
- Canada Joins California in Cancer Stem Cell Research, Donates $100 Million
- ImmunoCellular Therapeutics Announces Completion of Proof-of-Principle Studies Demonstrating Efficacy of Cancer Stem Cell Vaccine in Preclinical Model
- Raven and BTI Collaborate in Cancer Stem Cell Discovery
- Celprogen Launches Cancer Stem Cells
- Data Show Geron's Telomerase Inhibitor Cancer Drug is Active Against Cancer Stem Cells From Multiple Myeloma Patients
- Stanford Gets $20M Cancer-Stem Cell Site
- $20 Million Gift to Establish Cancer Stem Cell Research Center at Stanford
 |
 |
User Comments (0)
RSS Feeds